February 8, 2011

Tacrolimus Once Daily (ADVAGRAF) Versus Twice Daily (PROGRAF) in De Novo Renal Transplantation: A Randomized Phase III Study


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Advagraf is a once daily version of tacrolimus. This was randomized controlled non-inferiority trial comparing Advagraf to standard twice-daily tacrolimus. Patient and graft survival were not significantly different between the two groups. However, the difference in acute rejection episodes (higher with Advagraf) did not meet the non-inferiority threshold.
Renal Transplantation